| Autor: |
Kuang J; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA., Tao Y; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA.; Analytical Science Biologics, Takeda Pharmaceutical Company, Lexington, MA, 02421, USA., Song Y; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA.; Process Development & Manufacture Operations, GSK, MA, 02451, Waltham, USA., Chemmalil L; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA., Mussa N; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA.; Ultragenyx, CA, 94005, Brisbane, USA., Ding J; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA. julia.ding@bms.com., Li ZJ; Biologics Development Organization, Bristol-Myers Squibb Company, Devens, MA, 01434, USA. |
| Abstrakt: |
Isomerization of aspartic acid (Asp) in therapeutic proteins could lead to safety and efficacy concerns. Thus, accurate quantitation of various Asp isomerization along with kinetic understanding of the variant formations is needed to ensure optimal process development and sufficient product quality control. In this study, we first observed Asp-succinimide conversion in complementarity-determining regions (CDRs) Asp-Gly motif of a recombinant mAb through ion exchange chromatography, intact protein analysis by mass spectrometry, and LC-MS/MS. Then, we developed a specific peptide mapping method, with optimized sample digestion conditions, to accurately quantitate Asp-succinimide-isoAsp variants at peptide level without method-induced isomerization. Various kinetics of Asp-succinimide-isoAsp isomerization pathways were elucidated using 18 O labeling followed by LC-MS analysis. Molecular modeling and molecular dynamic simulation provide additional insight on the kinetics of Asp-succinimide formation and stability of succinimide intermediate. Findings of this work shed light on the molecular construct and the kinetics of the formation of isoAsp and succinimide in peptides and proteins, which facilitates analytical method development, protein engineering, and late phase development for commercialization of therapeutic proteins. |
